We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Says No-AG Agreements Are Antitrust Concerns a la Actavis
FTC Says No-AG Agreements Are Antitrust Concerns a la Actavis
August 19, 2013
Patent litigation settlements with “no-authorized generic” agreements qualify as “payment in return for staying out of the market” and should be considered an antitrust concern under the Supreme Court’s recent ruling in FTC v. Actavis, the Federal Trade Commission (FTC) says.